22 results about "Tooth disease" patented technology

Provided herein, in some embodiments, are methods and compositions for the treatment of Charcot-Marie-Tooth disease.

The invention relates to a flavonoid derivative containing a flavonoid that is coupled to an alkylene group via an ether bond, said alkylene group having an adhesion group for adhesion onto a dental surface. The flavonoid derivative has a long-term suppressing effect on the dental disease-causing formation of biofilm on the dental surfaces treated with the flavonoid derivative. The invention further relates to a kit for producing such a flavonoid derivative, and to the use of same.

Disclosed herein is a method for treating Charcot-Marie-Tooth disease (CMTD) involving administering (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid or a pharmaceutical composition thereof to a patient suffering from symptoms of CMTD. Also disclosed are pharmaceutical compositions and kits of parts containing (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid.

Disclosed herein are methods of treatment for Charcot–Marie–Tooth disease (CMTD) that involve administering (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid, or a pharmaceutical composition thereof, to a patient suffering from symptoms of CMTD. Pharmaceutical compositions and kits-to-parts including (2S)-2-[4-bromo-2-5 (1,2-oxazol-3-yl)phenoxy]propanoic acid are also disclosed.

The application discloses a kind of high-moisture composite protein meat paste of bean source and a preparation method thereof, and belongs to the technical field of food processing.The preparation method of the high-moisture composite protein meat paste of bean source provided by the application comprises the following steps: compounding pea protein and soybean protein, adjusting the ratio of the two, adding water and pre-emulsified vegetable oil during extrusion by means of extrusion technology, so that the moisture content is 67%-73%, the pre-emulsified vegetable oil content is 8%-12%, and after extrusion molding, cooling, cutting and packaging, the high-moisture composite protein meat paste of bean source is obtained.The high-moisture composite protein meat paste of bean source has high water content, soft taste, rich filamentous structure, soft and tender texture similar to meat paste, is easy to chew and swallow, and is especially suitable for people with dental diseases or people who like soft taste.

A method of treating Charcot Marie Tooth Disease in a human in need thereof. The method comprises systemically administering to the human a non-antibacterial tetracycline compound or antibacterial tetracycline compound, in an amount that is effective to treat Charcot Marie Tooth Disease but has substantially no antibacterial activity.

There is provided a compound of formula I, A-Q-BI wherein Q represents a structural fragment of formula II wherein: the wavy line and m have the meanings given in the description, and wherein A and B have the meanings given in the description, but may represent a peptide component having the following amino acid sequence: [(W) m-Lys-X1-T-(U) m-(X2) m-(Y) m] n-(W) m-Lys-X1-T-(U) m-(X2) m-(Y) m (SEQ ID No: 1); wherein n, m, T, W, X1, U, X2 and Y have the meanings given in the description, are useful in medicine, including as pharmaceutical excipients, adhesives and film-forming materials, and / or in the treatment of conditions characterized by inflammation, including wounds, burns and mucosal disorders such as anorectal diseases, inflammatory bowel diseases, gynecological diseases and dental diseases.

Disclosed herein are methods of treatment for Charcot–Marie–Tooth disease (CMTD) that involve administering (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid, or a pharmaceutical composition thereof, to a patient suffering from symptoms of CMTD. Pharmaceutical compositions and kits-to-parts including (2S)-2-[4-bromo-2-5 (1,2-oxazol-3-yl)phenoxy]propanoic acid are also disclosed.

The invention provides pure traditional Chinese medicine for treating oral and tooth diseases and belongs to the technical field of oral care, the tooth powder is prepared from multiple pure natural herbal plants such as astragalus membranaceus and pearl powder, does not contain harmful chemical components, is non-irritant to oral mucosa and is safe and reliable, all the materials are ground into powder through a medical grinding machine, and the granularity is controlled within a specific range. According to the tooth powder, the natural herbal active ingredients can be rapidly distributed in the oral cavity, the tooth powder has a certain treatment effect on various oral cavity problems such as tooth whitening, tooth strengthening and moth prevention, especially has a targeted effect on intractable and recurrent oral ulcers, and the tooth powder is simple in preparation method, low in cost, suitable for large-scale production and suitable for popularization and application. And the traditional Chinese medicine composition is suitable for different people to use and has a wide application prospect.

The present invention relates to the field of dental care products for dental, periodontal and / or any other oral conditions, or for cosmetic treatment. It provides an oral film (5), in particular a pharmaceutical oral film, useful for the simultaneous treatment of gums and teeth of a subject, for example for the treatment and / or prevention of periodontal and dental diseases or conditions, or for cosmetic treatment, such as tooth whitening. The invention also provides a method, such as a cosmetic method using the film and a method of making the oral film (5).

The invention discloses an oral cavity measurement system and an optical coherence tomography structure. The oral cavity measurement system comprises a plurality of light source generation modules, an image acquisition module, an imaging module, a reflector and a control module, the plurality of light source generation modules comprise a first light source generation module and a second light source generation module; the first light source generation module is used for generating a first light beam to the reflector; the second light source generation module is used for generating a second light beam to the reflector; the imaging module is used for imaging the first light beam and the second light beam reflected by the tooth to be detected to the image acquisition module; the image acquisition module is used for acquiring a first optical image formed by the first light beam through the imaging module and a second optical image formed by the second light beam through the imaging module; and the control module determines a three-dimensional point cloud picture of the tooth to be detected according to the first optical image and the second optical image. By means of the structure, the three-dimensional model of the tooth to be detected is established, tooth diseases are determined in time, and the accuracy and safety of oral cavity problem diagnosis are improved.

Disclosed herein are methods of treatment for Charcot–Marie–Tooth disease (CMTD) that involve administering (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid, or a pharmaceutical composition thereof, to a patient suffering from symptoms of CMTD. Pharmaceutical compositions and kits-to-parts including (2S)-2-[4-bromo-2-5 (1,2-oxazol-3-yl)phenoxy]propanoic acid are also disclosed.

The present invention relates to a system for regulating overexpression of PMP22 gene by a P1 promoter in patients with Charcot-Marie Tooth disease (CMT) to a normal level by using zinc finger protein (ZFP). Specifically, the present invention provides an isolated ZFP consisting of three or more zinc fingers and specifically reducing the expression of a PMP22 protein by a P1 promoter by binding to a promoter of the PMP22 gene or a part thereof in nervous system cells, or a polynucleotide encoding same. The present invention also provides novel transcriptional regulatory sequences for Schwann cell-specific expression of nucleic acid molecules encoding genes to be expressed in Schwann cells or proteins to be expressed in Schwann cells. The ZFP for regulating PMP22 gene expression according to the present invention or a polynucleotide encoding same can be used as a therapeutic agent for preventing or treating CMT disease, and can be more effectively expressed by the Schwann cell-specific transcriptional regulatory sequence.

A compound of formula I, L t - Q a - D b (I) wherein: Q a represents Z or A-Q-B, and Q is a structural fragment of formula II, (II) wherein: the wavy line, R and m have the meanings given in the description, and wherein A and B have the meanings given in the description, but can represent the peptide component of formula (IV), [(W) r - Lys-X 1 - T-U-X 2 - Y] n - (W) r - Lys-X 1 - T-U-X 2 - Y (IV) (SEQ ID No: 1) wherein n, r, T, W, X 1 , U, X 2 and Y have the meanings given in the description, each L independently represents a lipid as defined in the description, and D represents one or more optional montelukast moieties, is useful in medicine, including as a pharmaceutical excipient, adhesive and film forming material, and / or is useful in the treatment of conditions characterised by inflammation, including wounds, burns and mucosal disorders, such as anorectal disease, inflammatory bowel disease, gynaecological disease and dental disease.

Provided herein, in some embodiments, are methods and compositions for the treatment of Charcot-Marie-Tooth disease, comprising an inhibitor of a GCN2 pathway component.

The application belongs to the technical field of medicine and molecular biology, and particularly relates to application of BL-918 in preparation of a 2K drug for treating Charcot-Marie-Tooth disease, researches show that BL-918 can restore the impaired mitochondrial autophagy caused by GDAP1 defects and improve the motion phenotype of a GDAP1-related Charcot-Marie-Tooth disease zebrafish model. Meanwhile, BL-918 can significantly improve the mitochondrial function of Gdap1-deficient zebrafish, skin fibroblasts derived from Charcot-Marie-Tooth disease 2K patients and SH-SY5Y cells with GDAP1 knockdown. The application provides a new intervention method for treating Charcot-Marie-Tooth disease 2K and has important clinical application potential.

The present disclosure provides a tooth disease classification method based on federated learning (FL), including the following steps: S1: acquiring oral information of a user; S2: transmitting an oral dental image to a local server for preprocessing; S3: performing, by the single local server, model training according to a preprocessed oral dental image set and a model of a cloud master server; S4: transmitting trained model parameters to the cloud master server through digital encryption; and S5: performing, by each of local servers, fusion and classification according to digitally decrypted model parameters from the cloud master server. The method provided by the present disclosure has accurate classification, does not need to centrally process data, and keeps the oral information strictly secret without privacy disclosure; and meanwhile, the method encrypts the model parameters to further ensure the security.

Adeno-associated virus (AAV) expression vectors for the treatment of Charcot-Marie-Tooth disease are provided. The AAV expression vectors can have at least one neurofilament light chain gene (NEFL)-targeting shRNA operably linked to a first promoter and a NEFL cDNA operably linked to a second promoter. Pharmaceutical compositions comprising AAV expression vectors are also provided, as are methods of treating Charcot-Marie-Tooth disease type 2E.

The invention provides a computer-executed dental ray image analysis method, which comprises the following steps of: judging the orientation of a tooth root in a dental ray image by utilizing a trained first deep neural network, and adjusting the direction of the dental ray image according to the orientation of the tooth root, so that the orientation of the tooth root accords with a preset rule; segmenting teeth in the dental ray image by using a trained second deep neural network and distributing tooth numbers for the teeth; detecting tooth diseases and prostheses in the dental ray image by using a trained third deep neural network; using a trained fourth deep neural network to detect a tooth form abnormal part in the dental ray image; associating the detection results of the third and fourth deep neural networks with corresponding tooth numbers; generating a bounding box as a mask for a first tooth in the dental ray image; utilizing a trained fifth deep neural network to detect a junction point of enamel and dentin of the first tooth and a junction point of the first tooth and an alveolar bone based on the dental ray image and the mask; and calculating the absorption degree of the alveolar bone based on the detected junction point.

The present technology provides compositions and methods for enhancing mitochondrial networks in cells, particularly mammalian cells, and preferably human cells. The compositions and methods incorporate nanoparticles each including a mitochondrial network enhancing agent. When the nanoparticles are taken by the cell, the mitochondrial network enhancing agent binds to the mitofusin (MFN) proteins 1 and 2 thereby promoting fusion of mitochondria of the cell with one another and / or with endoplasmic reticulum of the cell. The present technology's compositions and methods find use in in the treatment of neurological, mitochondrial dysfunction, metabolic, and / or accelerated aging diseases or disorders including, for non-limiting examples, a progeroid syndrome, an MFN related disorder, Marie-Charcot Tooth disease, or any combination thereof.

Provided herein are compounds for inhibiting peripheral myelin protein 22 (PMP22) mRNA. Also provided herein are methods of using such compounds for the treatment of Charcot-Marie-Tooth disease.

Disclosed herein are methods of treating Charpy-Marithan-Fithussis disease (CMTD), the methods comprising administering (2S)-2-[4-bromo-2-(1, 2-oxazol-3-yl) phenoxy] propionic acid, or a pharmaceutical composition thereof, to a patient suffering from a symptom of CMTD. Also disclosed are pharmaceutical compositions and multi-component kits comprising (2S)-2-[4-bromo-2-(1, 2-oxazol-3-yl) phenoxy] propionic acid.